Author

Arghya Sadhukhan

Syngene International (India)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Organism:human· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

Kate S. Ashton· 2 shared Patrick Ryan PottsiD· 2 shared Rajiv Kapoor· 2 shared Robert G. GuenetteiD· 2 shared Shiqian LiiD· 2 shared Suresh Archunan· 2 shared Anh T. Tran· 1 shared Brian A. LanmaniD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Kate S. Ashton

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

LYMTACs: Chimeric Small Molecules Repurpose Lysosomal Membrane Proteins for Target Protein Relocalization and Degradation

Dhanusha A. Nalawansha, Georgios Mazis, Gitte Husemoen, Kate S. Ashton, Weixian Deng, Ryan P. Wurz, Anh T. Tran, Brian A. Lanman, Jiansong Xie, Robert G. Guenette, Shiqian Li, Christopher E. Smith, Suresh Archunan, Manoj K. Agnihotram, Arghya Sadhukhan, , Patrick Ryan Potts

This paper introduces LYMTACs, small molecules that use lysosomal membrane proteins to target and degrade membrane proteins, showing effectiveness against KRASG12D.

Nature Communications · Aug 21, 2025Peer-reviewedCancer Biology

VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation

Kyle Mangano, Robert G. Guenette, Spencer Hill, Shiqian Li, Jeffrey J. Liu, Cory M. Nadel, Suresh Archunan, Arghya Sadhukhan, Rajiv Kapoor, Seung Wook Yang, Kate S. Ashton, Patrick Ryan Potts

The paper demonstrates VIPER-TACs, which use viral E3 ligases to selectively degrade disease-specific proteins, reducing toxicity and expanding therapeutic options for targeted protein degradation.

Cell chemical biology · Mar 1, 2025Peer-reviewedCancer Biology